$DEST #Destiny Pharma plc ... Differentiated anti-infectives: Destiny Pharma’s FY 2019 results featured its ongoing Phase IIb study of its lead drug XF-73 for the prevention of post-operative staphylococcal infections and its prudent cash… https://t.co/hf8rRy6MZY #equity #stocks